Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02880371
Recruitment Status : Completed
First Posted : August 26, 2016
Last Update Posted : March 22, 2021
Sponsor:
Information provided by (Responsible Party):
Pfizer

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : October 24, 2019
Actual Study Completion Date : October 24, 2019